FDA Clears CryoLife’s New HeRO Dialysis Device

CryoLife, Inc. has received U.S. FDA 510(k) clearance for its next generation HeRO (Hemodialysis Reliable Outflow) device. The HeRO device is the only subcutaneous AV access solution clinically proven to maintain long-term access for end-stage renal disease (ERSD) hemodialysis patients with central venous stenosis.

CryoLife Receives FDA Clearance For Next Generation HeRO Device (via PR Newswire)

New Adaptor Allows Use with Early Access Arterial Grafts ATLANTA, April 4, 2013 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received U.S. Food and Drug Administration (FDA) 510…

published: April 16, 2013 in: Approval/Clearance, Vascular

Most read

Latest

^